Give Your Input on Impact of EU Clinical Trials Directive
ICREL allows you the opportunity to give your input through a survey about the EU Clinical Trials Directive.
Brussels, Belgium-June 9, 2008-ICREL is a one-year EU FP7 project, coordinated by EFGCP with further consortium members being EORTC under leadership of Denis Lacombe, ECRIN under leadership of Jacques Demotes, The Ethics Committee of the University of Vienna under leadership of Christiane Druml, and Hospital Clinic I de Barcelona under leadership of Xavier Carné. The project aims at analyzing the impact of the Clinical Trials Directive 2001/20/EC on clinical research in Europe.
ICREL has just launched a survey, giving sampled-out stakeholders (commercial and non-commercial sponsors, ethics committees, and competent authorities) the opportunity to have their experiences taken into account. As the results of this survey will form the basis for the European Commission Directorate Entreprise for their decisions on areas to be changed in the new clinical trials legislation it is very important that we collect as much information as possible. WE NEED YOUR SUPPORT!!!!
Please go to www.eortc.be/icrel and complete the questionnaire suitable for your type of organization.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Merck Stops HYPERION Trial for Winrevair in PAH Following Positive ZENITH Trial Results
January 30th 2025The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial hypertension, making it unethical to continue.
